SHORT COMMUNICATION
Recommendations for obstetric management and principles of cooperation between rheumatologists and obstetricians in systemic connective tissue disease patients
Submission date: 2014-02-10
Acceptance date: 2014-02-11
Online publication date: 2014-03-23
Publication date: 2014-02-28
Reumatologia 2014;52(1):38-48
KEYWORDS
TOPICS
ABSTRACT
Systemic connective tissue diseases, notably rheumatoid arthritis and systemic lupus erythematosus, frequently affect women of reproductive age. The significant impact of the diseases on the course of pregnancy is well established, and vice versa – the course of systemic connective tissue diseases may be affected by pregnancy. The risk of developing serious pregnancy complications and obstetric failures is markedly higher in the mentioned disease group. The foundation of obstetric success, i.e. giving birth to a healthy child and pregnancy having no effect on the course of a given autoimmune disease, is cooperation between rheumatologists and obstetricians so as to plan procreation at an optimal period and provide accurate pregnancy monitoring. The article delineates recommendations relating to contraception management, obstetric supervision and fetus wellbeing monitoring, from the point of view of the obstetrician.
REFERENCES (32)
1.
Borchers A, Naguwa S, Keen C, et al. The implications of autoimmunity and pregnancy. J Autoimmun 2010; 34: 287-299.
2.
Cutolo M, Sulli A, Straub R. Estrogen metabolism and autoimmunity. Autoimmun Rev 2012; 11: A460-A464.
3.
Schwarz EB, Manzi S. Risk of unintended pregnancy among women with systemic lupus erythematosus. Arthritis Rheum 2008; 59: 863-866.
4.
Middeldorp S. Thrombosis in women: what are the knowledge gaps in 2013? J Thromb Haemost 2013; 11 (suppl. 1): 180-191. .
5.
Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550-2558. .
6.
Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2539-2549. .
7.
Sanchez-Guerrero J, Karlson EW, Liang MH, et al. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1997; 5: 804-808.
8.
Bernier MO, Mikaeloff Y, Hudson M, Suissa S. Combined oral contraceptive use and the risk of systemic lupus erythematosus. Arthritis Rheum 2009; 61: 476-481.
9.
Strom BL, Reidenberg MM, West S, et al. Shingles, allergies, family medical history, oral contraceptives, and other potential risk factors for systemic lupus erythematosus. Am J Epidemiol 1994; 140: 632-642.
10.
Cooper GS, Dooley MA, Treadwell EL, et al. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study. Arthritis Rheum 2002; 46: 1830-1839.
11.
Karlson EW, Mandl LA, Hankinson SE, Grodstein F. Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the nurses’ health study. Arthritis Rheum 2004; 50: 3458-3467.
12.
Pikwer M, Bergström U, Nilsson JÅ, et al. Breast feeding, but not use of oral contraceptives, is associated with a reduced risk of rheumatoid arthritis. Ann Rheum Dis 2009; 68: 526-530. .
13.
Clowse M. Managing contraception and pregnancy in the rheumatologic diseases. Best Practice Res Clin Rheumatol 2010; 24: 373-385.
14.
Zawilska K, Bała M, Błedowski P i wsp. Polskie wytyczne profilaktyki i leczenia żylnej choroby zakrzepowo-zatorowej – aktualizacja 2012. Medycyna Praktyczna 2012; 10: 38-57.
15.
Empson MB, Lassere M, Craig JC, et al. Prevention of recurrent miscarriage for women with APS or lupus anticoagulant. Cochrane Database Syst Rev 2005; 2: CD002859.
16.
Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2006; 3: CD001449.
17.
Magee L. Treating hypertension in women of childbearing age and during pregnancy. Drug Safety 2001; 24: 457-447.
18.
Yamada H, Atsumi T, Kobashi G, et al. Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. J Rep Immunol 2009; 79: 188-195. .
19.
Le Thi Thuong D, Tieulié N, Costedoat N, et al. The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. Ann Rheum Dis 2005; 64: 273-278. .
20.
Hamela-Olkowska A, Dangel J. Ocena czasu przewodzenia przedsionkowo-komorowego metodą Dopplera pulsacyjnego u zdrowych płodów. Gin Pol 2009; 80: 584-589.
21.
Le Thi Huong D, Wechsler B, Vauthier-Brouzes D, et al. The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in SLE and/or APS. Rheumatology 2006; 45: 332-333.
22.
Cnossen JS, Morris RK, ter Riet G, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ 2008; 178: 701-711.
23.
Reide PJ, Yentis SM. Anaesthesia for the obstetric patient with non-obstetric systematic disease. Best Pract Res Clin Obstet Gynaecol 2010; 24: 313-326.
24.
Nicholson G, Burrin JM, Hall GM. Peri-operative steroid supplementation. Anaesthesia 1998; 53: 1091-1104.
25.
Friedman DM, Rupel A, Buyon JP. Epidemiology, etiology, detection and treatment of autoantibody-associated congenital heart block in neonatal lupus. Curr Rheumatol Rep 2007; 9: 101-108.
26.
Defendenti C, Atzeni F, Spina MF, et al. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmunity Rev 2011; 10: 150-154.
27.
Silverman E, Jaeggi E. Non-cardiac manifestations of neonatal lupus erythematosus. Scan J Immunol 2010; 72: 223-225.
28.
Aranegiu B, Batalla A, Florez A, et al. A case of SLE with cutaneous and cardiac involvement. J Am Acad Dermatol 2011; 2: 137.
29.
Salomonsson S, Strandberg L. Autoantibodies associated with congenital heart block. Scan J Immunol 2010; 72: 185-188. .
30.
Eliasson H, Sonesson SE, Sharland G, et al. Fetal Working Group of the European Association of Pediatric Cardiology. Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients. Circulation 2011; 124: 1919-1926.
31.
Friedman DM, Kim MY, Copel AJ, et al. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol 2009; 103: 1102-1106.
32.
Hutter D, Silverman ED, Jaeggi ET. The benefits of transplacental treatment of isolated congenital CHB associated with maternal anti-Ro/SSA antibodies: a review. Scan J Immunol 2010; 72: 235-241.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
